Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of TG-2349 Capsule vs Solution in Healthy Volunteers
NCT02108418Phase 1Completed
- Sponsor
- TaiGen Biotechnology Co., Ltd.
- Start
- Apr 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of furaprevir in chronic hepatitis C (CHC) (2 arms), sponsored by TaiGen Biotechnology Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 120 hours, Area Under the Concentration-Time Curve From Time Zero to Infinity at 120 hours and 1 more. Started Apr 2014; status: completed.
02
Drugs
furaprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT02108418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108418.